<html xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2004/07/xpath-functions" xmlns:xdt="http://www.w3.org/2004/07/xpath-datatypes"><head><title>HEALTH AND SAFETY CODE  CHAPTER 51.  CANCER CLINICAL TRIAL PARTICIPATION PROGRAM</title><style type='text/css'>.center {text-align: center; }.right {text-align: right; }.left{text-align: left; }.justify{text-align: justify;  }.heading{font-weight: bold; }body{background-color: #ffffff;color: #000000;}p{margin-top:0em;margin-bottom: 0em;font-family: Courier New,arial,helvetica,sans-serif;font-size: 12pt;line-height: 1.5em;clear: both;}pre {white-space: -moz-pre-wrap; white-space: -pre-wrap; white-space: -o-pre-wrap; white-space: pre-wrap; word-wrap:    break-word; }div{margin-top: 0em;margin-bottom: 0em;font-family: Courier New,arial,helvetica,sans-serif;font-size: 12pt;line-height: 1.5em;}div.full{    clear: both;}div.left{float: left;width: 75%;  margin-right: 1.67em;padding-top: 0em;padding-right: 1em;line-height: 1.5em;}div.right{margin-left: 75%;text-align: right;padding-top: 0em;padding-right:2em;line-height: 1.5em;vertical-align: text-bottom;}a:link {text-decoration: none;}a:visited{text-decoration: none;}a:hover{text-decoration: none;}a:active{text-decoration: none;}</style></head><body><pre xml:space="preserve">	
					
<p class="center">HEALTH AND SAFETY CODE</p><br /><p class="center">TITLE 2. HEALTH</p><br /><p class="center">SUBTITLE B.  HEALTH PROGRAMS</p><br /><p style="text-indent:7ex;" class="center">CHAPTER 51.  CANCER CLINICAL TRIAL PARTICIPATION PROGRAM</p><br /><p class="left"><a name="51.0001"></a><a name="184958.186381"></a></p><p style="text-indent:7ex;" class="left">Sec. 51.0001.  DEFINITIONS.  In this chapter:</p><p style="text-indent:13ex;" class="left">(1)  "Cancer clinical trial" means a research study that subjects an individual to a new cancer treatment, including a medication, chemotherapy, adult stem cell therapy, or other treatment.</p><p style="text-indent:13ex;" class="left">(2)  "Inducement" means the payment of money, including a lump-sum or salary payment, to an individual for the individual's participation in a cancer clinical trial.</p><p style="text-indent:13ex;" class="left">(3)  "Program" means the cancer clinical trial participation program established under this chapter.</p><p style="text-indent:13ex;" class="left">(4)  "Subject" means an individual who participates in the program.</p>
<p class="left">Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/86R/billtext/html/HB03147F.HTM">3147</a>), Sec. 2, eff. September 1, 2019.</p><p class="left">Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.001(53), eff. September 1, 2021.</p>

<p class="left"><a name="51.0002"></a><a name="184959.186381"></a></p><p style="text-indent:7ex;" class="left">Sec. 51.0002.  ESTABLISHMENT.  An independent, third-party organization may develop and implement the cancer clinical trial participation program to provide reimbursement to subjects for ancillary costs associated with participation in a cancer clinical trial, including costs for:</p><p style="text-indent:13ex;" class="left">(1)  travel;</p><p style="text-indent:13ex;" class="left">(2)  lodging;</p><p style="text-indent:13ex;" class="left">(3)  parking and tolls; and</p><p style="text-indent:13ex;" class="left">(4)  other costs considered appropriate by the organization.</p>
<p class="left">Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/86R/billtext/html/HB03147F.HTM">3147</a>), Sec. 2, eff. September 1, 2019.</p><p class="left">Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.001(53), eff. September 1, 2021.</p>

<p class="left"><a name="51.0003"></a><a name="184960.186381"></a></p><p style="text-indent:7ex;" class="left">Sec. 51.0003.  REQUIREMENTS; NOTICE.  (a)  The program:</p><p style="text-indent:13ex;" class="left">(1)  must collaborate with physicians and health care providers to notify a prospective subject about the program when:</p><p style="text-indent:19ex;" class="left">(A)  the prospective subject provides informed consent for a cancer clinical trial; or</p><p style="text-indent:19ex;" class="left">(B)  funding is available to provide the program for the cancer clinical trial in which the prospective subject participates;</p><p style="text-indent:13ex;" class="left">(2)  must reimburse subjects based on financial need, which may include reimbursement to subjects whose income is at or below 700 percent of the federal poverty level;</p><p style="text-indent:13ex;" class="left">(3)  must provide reimbursement for ancillary costs, including costs described by Section <a target="new" href="https://statutes.capitol.texas.gov/GetStatute.aspx?Code=HS&amp;Value=51.0002">51.0002</a>, to eliminate the financial barriers to enrollment in a clinical trial;</p><p style="text-indent:13ex;" class="left">(4)  may provide reimbursement for reasonable ancillary costs, including costs described by Section <a target="new" href="https://statutes.capitol.texas.gov/GetStatute.aspx?Code=HS&amp;Value=51.0002">51.0002</a>, to one family member, friend, or other person who attends a cancer clinical trial to support a subject; and</p><p style="text-indent:13ex;" class="left">(5)  must comply with applicable federal and state laws.</p><p style="text-indent:7ex;" class="left">(b)  The independent, third-party organization administering the program shall provide written notice to prospective subjects of the requirements described by Subsection (a).</p>
<p class="left">Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/86R/billtext/html/HB03147F.HTM">3147</a>), Sec. 2, eff. September 1, 2019.</p><p class="left">Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.001(53), eff. September 1, 2021.</p><p class="left">Amended by: </p><p style="text-indent:7ex;" class="left">Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.002(9), eff. September 1, 2021.</p>

<p class="left"><a name="50.0004"></a><a name="184961.186381"></a></p><p style="text-indent:7ex;" class="left">Sec. 51.0004.  REIMBURSEMENT REQUIREMENTS; NOTICE.  (a)  A reimbursement under the program must:</p><p style="text-indent:13ex;" class="left">(1)  be reviewed and approved by the institutional review board associated with the cancer clinical trial for which the reimbursement is provided; and</p><p style="text-indent:13ex;" class="left">(2)  comply with applicable federal and state laws.</p><p style="text-indent:7ex;" class="left">(b)  The independent, third-party organization operating the program is not required to obtain approval from an institutional review board on the financial eligibility of a subject who is medically eligible for the program.</p><p style="text-indent:7ex;" class="left">(c)  The independent, third-party organization operating the program shall provide written notice to a subject on:</p><p style="text-indent:13ex;" class="left">(1)  the nature and availability of the ancillary financial support under the program; and </p><p style="text-indent:13ex;" class="left">(2)  the program's general guidelines on financial eligibility.</p>
<p class="left">Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/86R/billtext/html/HB03147F.HTM">3147</a>), Sec. 2, eff. September 1, 2019.</p><p class="left">Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.001(53), eff. September 1, 2021.</p>

<p class="left"><a name="50.0005"></a><a name="184962.186381"></a></p><p style="text-indent:7ex;" class="left">Sec. 51.0005.  REIMBURSEMENT STATUS AS INDUCEMENT.  Reimbursement to a subject of ancillary costs under the program:</p><p style="text-indent:13ex;" class="left">(1)  does not constitute an inducement to participate in a cancer clinical trial;</p><p style="text-indent:13ex;" class="left">(2)  is not considered coercion or the exertion of undue influence to participate in a cancer clinical trial; and</p><p style="text-indent:13ex;" class="left">(3)  is meant to accomplish parity in access to cancer clinical trials and remove barriers to participation in cancer clinical trials for financially burdened subjects.</p>
<p class="left">Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/86R/billtext/html/HB03147F.HTM">3147</a>), Sec. 2, eff. September 1, 2019.</p><p class="left">Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.001(53), eff. September 1, 2021.</p>

<p class="left"><a name="51.0006"></a><a name="184963.186381"></a></p><p style="text-indent:7ex;" class="left">Sec. 51.0006.  FUNDING.  The independent, third-party organization that administers the program may accept gifts, grants, and donations from any public or private source to implement this chapter.</p>
<p class="left">Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/86R/billtext/html/HB03147F.HTM">3147</a>), Sec. 2, eff. September 1, 2019.</p><p class="left">Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.001(53), eff. September 1, 2021.</p>

<p class="left"><a name="51.0007"></a><a name="184964.186381"></a></p><p style="text-indent:7ex;" class="left">Sec. 51.0007.  COLLABORATION.  The independent, third-party organization that administers the program may collaborate with the Cancer Prevention and Research Institute of Texas established under Chapter <a target="new" href="https://statutes.capitol.texas.gov/GetStatute.aspx?Code=HS&amp;Value=102">102</a> to provide reimbursement under the program.</p>
<p class="left">Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/86R/billtext/html/HB03147F.HTM">3147</a>), Sec. 2, eff. September 1, 2019.</p><p class="left">Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. <a target="new" href="http://www.legis.state.tx.us/tlodocs/87R/billtext/html/HB03607F.HTM">3607</a>), Sec. 21.001(53), eff. September 1, 2021.</p>


				</pre></body></html>